Literature DB >> 26692290

Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.

Theresa D Ahrens1,2, Sylvia Timme1, Jenny Ostendorp1, Lioudmilla Bogatyreva3, Jens Hoeppner4, Ulrich T Hopt4, Dieter Hauschke3, Martin Werner1,5, Silke Lassmann1,5,6.   

Abstract

We previously showed that histone deacetylase inhibitor (HDACi) and 5-azacytidine (AZA) treatment selectively induced cell death of esophageal cancer cells. The mechanisms of cancer selectivity, however, remained unclear. Here we examined whether the cancer selectivity of HDACi/AZA treatment is mediated by the thioredoxin (Trx) system and reactive oxygen species (ROS) in esophageal cancer cells. For this, we first analyzed human tissue specimens of 37 esophageal cancer patients by immunohistochemistry for Trx, Trx-interacting protein (TXNIP) and Trx reductase (TXNRD). This revealed a loss or at least reduction of nuclear Trx in esophageal cancer cells, compared with normal epithelial cells (P<0.001). Although no differences were observed for TXNIP, TXNRD was more frequently expressed in cancer cells (P<0.001). In the two main histotypes of esophageal squamous cell carcinomas (ESCCs, n=19) and esophageal adenomcarcinomas (EAC, n=16), similar Trx, TXNIP and TXNRD expression patterns were observed. Also in vitro, nuclear Trx was only detectable in non-neoplastic Het-1A cells, but not in OE21/ESCC or OE33/EAC cell lines. Moreover, the two cancer cell lines showed an increased Trx activity, being significant for OE21 (P=0.0237). After treatment with HDACi and/or AZA, ROS were exclusively increased in both cancer cell lines (P=0.048-0.017), with parallel decrease of Trx activity. This was variably accompanied by increased TXNIP levels upon AZA, MS-275 or MS-275/AZA treatment for 6 or 24 h in OE21, but not in Het-1A or OE33 cells. In summary, this study evaluated Trx and its associated proteins TXNIP and TXNRD for the first time in esophageal cancers. The analyses revealed an altered subcellular localization of Trx and strong upregulation of TXNRD in esophageal cancer cells. Moreover, HDACi and AZA disrupted Trx function and induced accumulation of ROS with subsequent apoptosis in esophageal cancer cells exclusively. Trx function is hence an important cellular mediator conferring non-neoplastic cell resistance for HDACi and/or AZA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26692290     DOI: 10.1038/labinvest.2015.148

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  39 in total

1.  Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells.

Authors:  Ju-Hee Lee; Eun-Goo Jeong; Moon-Chang Choi; Sung-Hak Kim; Jung-Hyun Park; Sang-Hyun Song; Jinah Park; Yung-Jue Bang; Tae-You Kim
Journal:  Mol Cells       Date:  2010-07-23       Impact factor: 5.034

2.  Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer.

Authors:  Caroline M Woolston; Sarah J Storr; Ian O Ellis; David A L Morgan; Stewart G Martin
Journal:  Radiother Oncol       Date:  2011-08       Impact factor: 6.280

3.  Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion in human MDA-MB-231 breast cancer cells.

Authors:  Antonietta R Farina; Lucia Cappabianca; Giuseppina DeSantis; Natalia Di Ianni; Pierdomenico Ruggeri; Marzia Ragone; Stefania Merolle; Kathryn F Tonissen; Alberto Gulino; Andrew R Mackay
Journal:  FEBS Lett       Date:  2011-09-28       Impact factor: 4.124

4.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.

Authors:  Jing-jing Liu; Qing Liu; Hu-lai Wei; Juan Yi; Huai-shun Zhao; Li-ping Gao
Journal:  Pharmazie       Date:  2011-06       Impact factor: 1.267

Review 5.  Epigenetics in esophageal cancers.

Authors:  Theresa D Ahrens; Martin Werner; Silke Lassmann
Journal:  Cell Tissue Res       Date:  2014-05-10       Impact factor: 5.249

6.  Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.

Authors:  Yasushi Toh; Manabu Yamamoto; Kazuya Endo; Yasuharu Ikeda; Hideo Baba; Shunji Kohnoe; Hirotoshi Yonemasu; Yoichi Hachitanda; Takeshi Okamura; Keizo Sugimachi
Journal:  Oncol Rep       Date:  2003 Mar-Apr       Impact factor: 3.906

7.  High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy.

Authors:  Sofi E Eriksson; Stefanie Prast-Nielsen; Emilie Flaberg; Laszlo Szekely; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2009-09-17       Impact factor: 7.376

8.  Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma.

Authors:  Motoaki Nagano; Kinta Hatakeyama; Masahiro Kai; Hajime Nakamura; Junji Yodoi; Yujiro Asada; Kazuo Chijiiwa
Journal:  HPB (Oxford)       Date:  2012-06-08       Impact factor: 3.647

9.  Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1.

Authors:  Jason M Hansen; Walter H Watson; Dean P Jones
Journal:  Toxicol Sci       Date:  2004-07-28       Impact factor: 4.849

10.  Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells.

Authors:  Christiane D Fichter; Corinna Herz; Claudia Münch; Oliver G Opitz; Martin Werner; Silke Lassmann
Journal:  BMC Cell Biol       Date:  2011-04-06       Impact factor: 4.241

View more
  7 in total

1.  Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition.

Authors:  E Hendrick; P Peixoto; A Blomme; C Polese; N Matheus; J Cimino; A Frère; A Mouithys-Mickalad; D Serteyn; L Bettendorff; B Elmoualij; P De Tullio; G Eppe; F Dequiedt; V Castronovo; D Mottet
Journal:  Oncogene       Date:  2017-04-17       Impact factor: 9.867

Review 2.  The production of 3D tumor spheroids for cancer drug discovery.

Authors:  Shilpa Sant; Paul A Johnston
Journal:  Drug Discov Today Technol       Date:  2017-04-14

3.  High Content Screening Characterization of Head and Neck Squamous Cell Carcinoma Multicellular Tumor Spheroid Cultures Generated in 384-Well Ultra-Low Attachment Plates to Screen for Better Cancer Drug Leads.

Authors:  Stanton J Kochanek; David A Close; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2018-12-28       Impact factor: 1.738

4.  Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.

Authors:  Paul L Feingold; Deborah R Surman; Kate Brown; Yuan Xu; Lucas A McDuffie; Vivek Shukla; Emily S Reardon; Daniel R Crooks; Jane B Trepel; Sunmin Lee; Min-Jung Lee; Shaojian Gao; Sichuan Xi; Kaitlin C McLoughlin; Laurence P Diggs; David G Beer; Derek J Nancarrow; Leonard M Neckers; Jeremy L Davis; Chuong D Hoang; Jonathan M Hernandez; David S Schrump; R Taylor Ripley
Journal:  Mol Cancer Ther       Date:  2018-06-22       Impact factor: 6.261

5.  Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress.

Authors:  Ying Huang; Wuping Yang; Huihong Zeng; Chuan Hu; Yaqiong Zhang; Nanhua Ding; Guangqin Fan; Lijian Shao; Bohai Kuang
Journal:  Cell Mol Biol Lett       Date:  2018-07-28       Impact factor: 5.787

6.  Synergistic induction of apoptosis in a cell model of human leukemia K562 by nitroglycerine and valproic acid.

Authors:  Shahin Aalaei; Mehdi Mohammadzadeh; Yaghub Pazhang
Journal:  EXCLI J       Date:  2019-08-15       Impact factor: 4.068

7.  Downregulation of miR-135b-5p Suppresses Progression of Esophageal Cancer and Contributes to the Effect of Cisplatin.

Authors:  Yuzhu Di; Yanan Jiang; Xiuyun Shen; Jing Liu; Yang Gao; Huimin Cai; Xiaoli Sun; Dandan Ning; Bing Liu; Jiaji Lei; Shizhu Jin
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.